Molecular Characterization of Drug-Resistant Mycobacterium tuberculosis Isolated from HIV-Positive Patients in Rivers State, Nigeria
Asian Journal of Research in Infectious Diseases,
Page 44-51
DOI:
10.9734/ajrid/2021/v6i430204
Abstract
Background: Drug resistant tuberculosis is a major challenge in the global bid to control the disease burden and improve treatment outcomes of DRTB infected individuals.
Aim: To determine the molecular characteristics and pattern of drug resistance to first line anti-tuberculosis drugs in HIV sero-positive patients in River State using line probe assay.
Methods: The Line Probe Assay (LPA) was used to assess the drug resistance pattern and gene mutations in 260 sputum specimens collected consecutively from 260 adult, HIV sero-positive subjects presenting with symptoms suggestive of TB in clinical settings across Rivers State, Nigeria.
Results: The results showed a 61.2% (n = 159) prevalence of TB among all study subjects. LPA analysis showed that 16 (10.1%) were multidrug resistant strains, 17 (10.7%) Rifampicin (RIF) monoresistant strains, 24 (15.1%) Isonaizid (INH) monoresistant strains and 102 (64.2%) drug susceptible strains. Among all 33 RIF-resistant strains, 24 (75%) had a mutation in rpoB S531L at the MUT3 band. Another mutation was observed at rpoB H526D (1/17) in RIF-monoresistant strains but not in MDR-TB strains. In INH resistant strains, mutations were observed at the katG gene [32/39 (82.1%)] which constituted 13/15 (86.7%) in MDR-TB strains and 19/24 (79.2%) in INH-monoresistant strains (p =0.002). Overall frequency of inhA mutation was 6/39 (15.4%); MDR-TB strains [2/15 (13.3%)] and INH-monoresistant strains [4/24 (16.7%), p = 0.2]. Combined KatG and inhA mutation was found in 1/39 (2.6%) of INH-monoresistant strains and in none of MDR-TB strains. Of the single inhA mutation bands, only 1/39 (4.2%) MUT 3B (T8A mutation) was observed in INH-monoresistant strains.
Conclusion: The results showed that drug-resistant TB is prevalent in Rivers State with various gene mutations observed in the different TB strains isolated, making LPA analysis a necessity in the bid to improving prevention and control efforts in the region.
Keywords:
- Mycobacterium tuberculosis
- HIV
- drug resistance
- MDRTB
- rifampicin
- isonaizid
- line probe assay
How to Cite
References
Yorsangsukkamol J, Chaiprasert A, Prammananan T, Palittapongarnpim P, Limsoontarakul S, Prayoonwiwat N. Molecular analysis of Mycobacterium tuberculosis from tuberculous meningitis patients in Thailand. Tuberc Edinb Scotl. 2009;89(4):304–9.
World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization; 2017.
Millet J-P, Moreno A, Fina L, del Baño L, Orcau A, de Olalla PG, et al. Factors that influence current tuberculosis epidemiology. Eur Spine J. 2013;22(Suppl 4):539–48.
Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally Drug-Resistant Tuberculosis in India. Clin Infect Dis. 2012 Feb 15;54(4):579–81.
Klopper M, Warren RM, Hayes C, Gey van Pittius NC, Streicher EM, Müller B, et al. Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa. Emerg Infect Dis. 2013;19(3):449–55.
Okorie AJ, Gidado M, Akang G, Ubochioma E, Rupert E, Ibeziako V, Meribole E, Osakwe P. The Prevalence of Drug-Resistant Tuberculosis among People Living with HIV (PLHIV) in Abia State Onuka. Advances in Infectious Diseases. 2016; 6: 63-69
Myneedu DVP, Singhal R, Khayyam RU, Sharma PP, Bhalla M, Behera D, Sarin R. First and second line drug resistance among treatment naıve pulmonary tuberculosis patients in a district under Revised National Tuberculosis Control Programme (RNTCP) in New. Journal of Epidemiology and Global Health.2015;5:365– 373
Okorie O, John A, Gidado M, Akang G, Emperor U, Rupert E, Vivian I, Meribole E, Osakwe P. The Prevalence of Drug-Resistant Tuberculosis among People Living with HIV (PLHIV) in Abia State. Advances in Infectious Diseases. 2016;6:63-69.
Erhabor O, Jeremiah ZA, Adias TC, Okere C. The prevalence of human immunodeficiency virus infection among TB patients in Port Harcourt Nigeria. HIV/AIDS. 2010;2:1–5.
Nwofor AC, Nyamngee A , Nwabuisi C , Iwakun M , Gidado M , Mensah C , et al. Performance of Genotype MTBDRplus in the Detection of Resistance to Rifampicin and Isoniazid among Clinical Mycobacteria Isolates in Ilorin, Nigeria. Curr HIV Res. 2015;13:308-314.
Gao J, Zheng P, Fu H. Prevalence of TB/HIV Co-Infection in Countries Except China: A Systematic Review and Meta-Analysis. PLoS ONE. 2013;8(5):e64915
Samo Gudo P, Cuna Z, Coelho E, Maungate S, Borroni E, Miotto P, et al. Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey. Eur Respir J. 2011;38(1):222–4.
Haeili M, Darban Sarokhalil D, Fooladi AAI, Javadpour S, Hashemi A, Siavoshi F, et al. Spoligotyping and drug resistance patterns of Mycobacterium tuberculosis isolates from five provinces of Iran. Microbiology Open 2013;2:988-996.
Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K, et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2012;56:3047–3053.
DOI: 10.1128/AAC.06460-11
Munir A, Kumar N, Ramalingam SB, Tamilzhalagan S, Shanmugam SK, Palaniappan AN, et al. Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India. Sci Rep. 2019;9(1):10283.
DOI: 10.1038/s41598-019-46756-x
PMID: 31311987
PMCID: PMC6635374
Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE,et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004; 8(11):1382-4.
Kibret KT, Moges Y, Memiah P and Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017; 6(1):7.
DOI: 10.1186/s40249-016-0214-x
World Health Organization Global Tuberculosis Report ;2020.
Available: https://www.who.int/tb/publications/global_report/TB20_Exec_Sum_20201014.pdf
GenoType®MTBDRplus. Molecular genetic assay for identification of resistance to rifampicin and/or Isoniazid of the Mycobacterium tuberculosis complex. Version 2.0. Hain Life science GmbH Nehren Germny; 2009.
Available at: www.hain-lifescience.de
Dinic L, Akande P, Idigbe EO, Ani A, Onwujekwe D, Agbaji O, et al. Genetic Determinants of Drug-Resistant Tuberculosis among HIV Infected Patients in Nigeria. J. Clin. Microbiol. 2012; 2905–2909
Otu A, Umoh V, Habib A, Ameh S, Lawson L and Ansa V. Drug Resistance among Pulmonary Tuberculosis Patients in Calabar , Nigeria. Pulmonary Medicine. 2013.
Available:http://dx.doi.org/10.1155/2013/235190
Barnard M, Albert H, Coetzee G, Brien R, Bosman ME. Rapid Molecular screening for multi-drug resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008;177:787-792.
Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, et al. Rapid screening of MDR-TB using molecular line probe assay is feasible in Uganda. BMC Infect Dis. 2010;10:41.
Huyen MNT, Tiemersma EW, Nguyen TNL, Cobelens FGJ, Nguyen HD, Sy DH, et al. Validation of the GenoType MTBDRplus assay for diagnosis of multi-drug resistant tuberculosis in South Vietnam. BMC Infect Dis. 2010;10: 149
Mariga JP and Odeigah PGC. Clinical assessment of isoniazid (INH) acetylator phenotype of Mycobacterium tuberculosis infected patients in Alushi Akwanga. Biotech Res. 2009;6:101-106.
Crudu V, Stratan E, Romancenco E, Allerheiligen V, Hillemann A and Moraru N. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J. Clin. Microbiol. 2012;50: 1264 –1269.
Shah NS, Pratt P, Armstrong L, Robison V, Castro KG, and Cegielski JP. Extensively drug-resistant tuberculosis in the United States, 1993-2007. J of Am Med Assoc. 2008;300(18): 2153-2160
Smith SE, Kurbatova EV, Cavanaugh JS and Cegielski JP. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int. J. Tuberc. Lung Dis. 2012;16: 203–205.
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazina-mide (Z) (NC-003).
Available:https://clinicaltrials.gov/ct2/show/NCT01691534?term=NC003&rank=1 (accessed 7th June, 2017).
Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diary lquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 2009;360:2397–2405.
-
Abstract View: 572 times
PDF Download: 357 times
